Catégorie : Recherche

uniQure a annoncé qu'elle reprenait le recrutement des patients à la dose la plus élevée de l'essai AMT-130.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences annonce une mise à jour positive de l'essai de phase 1b/2a SELECT-HD avec des résultats initiaux indiquant l'engagement de cibles sélectivement alléliques avec WVE-003 dans la maladie de Huntington.

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure annonce une mise à jour sur la cohorte à faible dose de l'essai clinique de phase I/II de la thérapie génique AMT-130 pour le traitement de la maladie de Huntington.

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences met à jour les résultats des essais

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Webinar - Tout ce que vous devez savoir sur Proof-HD

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]

Dernières nouvelles - Roche prévoit une nouvelle étude sur le Tominersen

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]